FTSJD2 Activators comprise of chemicals that modulate cellular signaling pathways, which in turn could influence the activity of the protein FTSJD2. They commonly function by either directly activating key enzymes in signaling pathways, such as adenylate cyclase or protein kinase C, or by altering intracellular levels of second messengers such as cAMP or calcium ions. For instance, forskolin directly activates adenylate cyclase, leading to an increase in cAMP and subsequent activation of cAMP-dependent protein kinase A (PKA). PKA is known to phosphorylate a myriad of cellular proteins, regulating their activity.
Moreover, compounds such as IBMX and sodium orthovanadate work by inhibiting the breakdown of cAMP or by inhibiting phosphatases, respectively, thus maintaining the phosphorylation status of proteins within the cell. The increase in phosphorylated proteins can affect numerous signaling pathways, suggesting that these activators could indirectly enhance the activity of FTSJD2 is regulated by phosphorylation. Anisomycin, by activating stress-activated protein kinases, and 5-Azacytidine, through epigenetic modulation of gene expression, exemplify the breadth of mechanisms by which these activators can exert their influence on cellular proteins.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Activates adenylate cyclase, increasing cAMP levels which can lead to protein kinase A activation that may enhance the phosphorylation and thus the activity of various proteins within the cell. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Direct activator of protein kinase C (PKC) which could modulate the activity of proteins by phosphorylation in related signaling pathways. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Increases intracellular calcium concentration, potentially modulating calcium-dependent protein kinases and phosphatases that could alter protein function. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
A cAMP analog that can activate PKA and modulate various proteins through phosphorylation within its signaling pathways. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Another cAMP analog that serves similar functions as 8-Br-cAMP in activating PKA and influencing associated signaling pathways. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
A synthetic catecholamine that acts as an agonist for beta-adrenergic receptors, potentially increasing cAMP and activating PKA, impacting various signaling processes. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
A non-selective inhibitor of phosphodiesterases, thereby preventing cAMP degradation which can result in PKA activation and subsequent phosphorylation of proteins. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A calcium ionophore that increases intracellular calcium and can influence calcium-dependent proteins and signaling pathways. | ||||||
Sodium Orthovanadate | 13721-39-6 | sc-3540 sc-3540B sc-3540A | 5 g 10 g 50 g | $49.00 $57.00 $187.00 | 142 | |
Inhibits protein tyrosine phosphatases, possibly maintaining or enhancing the phosphorylation state of proteins within the cell. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Acts as a protein synthesis inhibitor, but can also activate stress-activated protein kinases, potentially influencing signaling pathways. | ||||||